Pomanda estimates the enterprise value of NUVISION BIOTHERAPIES LIMITED at £2.9m based on a Turnover of £2.6m and 1.12x industry multiple (adjusted for size and gross margin).
nuvision biotherapies limitedEstimated Valuation
£0
Pomanda estimates the enterprise value of NUVISION BIOTHERAPIES LIMITED at £0 based on an EBITDA of £-1.6m and a 4.8x industry multiple (adjusted for size and gross margin).
nuvision biotherapies limitedEstimated Valuation
£0
Pomanda estimates the enterprise value of NUVISION BIOTHERAPIES LIMITED at £0 based on Net Assets of £-177k and 1.77x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Nuvision Biotherapies LimitedOverview
Nuvision Biotherapies Limited is a live company located in nottingham, NG90 6BH with a Companies House number of 09526225. It operates in the manufacture of pharmaceutical preparations sector, SIC Code 21200. Founded in April 2015, it's largest shareholder is
meif proof of concept & early stage lp
with a 19.3% stake. Nuvision Biotherapies Limited is a established,
small sized company, Pomanda has estimated its turnover at
£2.6m with
high
growth in recent years.
Pomanda's financial health check has awarded Nuvision Biotherapies Limited a 3 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 6 areas for improvement. Company Health Check FAQs
Health Rating3out of 5
4 Strong
2 Regular
6 Weak
Size
annual sales of £2.6m, make it smaller than the average company (£34.4m)
£2.6m - Nuvision Biotherapies Limited
£34.4m - Industry AVG
Growth
3 year (CAGR) sales growth of 28%, show it is growing at a faster rate (3.7%)
28% - Nuvision Biotherapies Limited
3.7% - Industry AVG
Production
with a gross margin of 32.8%, this company has a comparable cost of product (32.8%)
32.8% - Nuvision Biotherapies Limited
32.8% - Industry AVG
Profitability
an operating margin of -62% make it less profitable than the average company (8.8%)
-62% - Nuvision Biotherapies Limited
8.8% - Industry AVG
Employees
with 21 employees, this is below the industry average (93)
21 - Nuvision Biotherapies Limited
93 - Industry AVG
Pay Structure
on an average salary of £67.4k, the company has an equivalent pay structure (£67.4k)
£67.4k - Nuvision Biotherapies Limited
£67.4k - Industry AVG
Efficiency
resulting in sales per employee of £123k, this is less efficient (£370.1k)
£123k - Nuvision Biotherapies Limited
£370.1k - Industry AVG
Debtor Days
it gets paid by customers after 15 days, this is earlier than average (47 days)
15 days - Nuvision Biotherapies Limited
47 days - Industry AVG
Creditor Days
its suppliers are paid after 40 days, this is slower than average (33 days)
40 days - Nuvision Biotherapies Limited
33 days - Industry AVG
Stock Days
it holds stock equivalent to 42 days, this is less than average (110 days)
42 days - Nuvision Biotherapies Limited
110 days - Industry AVG
Cash Balance
has cash to cover current liabilities
for 5 weeks, this is less cash available to meet short term requirements (10 weeks)
5 weeks - Nuvision Biotherapies Limited
10 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 141.1%, this is a higher level of debt than the average (43.5%)
141.1% - Nuvision Biotherapies Limited
43.5% - Industry AVG
NUVISION BIOTHERAPIES LIMITED financials
EXPORT
Nuvision Biotherapies Limited's latest turnover from June 2024 is estimated at £2.6 million and the company has net assets of -£177 thousand. According to their latest financial statements, Nuvision Biotherapies Limited has 21 employees and maintains cash reserves of £44.3 thousand as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Jun 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Mar 2019
Mar 2018
Mar 2017
Mar 2016
Turnover
2,583,318
1,812,244
1,200,748
1,225,858
2,157,464
1,378,604
916,615
857,481
394,856
Other Income Or Grants
Cost Of Sales
1,737,319
1,214,037
786,462
788,683
1,338,266
818,266
521,138
485,187
234,347
Gross Profit
845,999
598,207
414,286
437,176
819,197
560,338
395,476
372,294
160,509
Admin Expenses
2,447,326
1,540,899
1,625,335
1,454,934
1,811,373
1,066,030
652,626
698,429
333,728
Operating Profit
-1,601,327
-942,692
-1,211,049
-1,017,758
-992,176
-505,692
-257,150
-326,135
-173,219
Interest Payable
2,994
3,844
3,122
1,525
1,525
1,688
Interest Receivable
18,112
28,028
6,364
595
106
1,210
716
162
300
Pre-Tax Profit
-1,586,209
-918,508
-1,207,807
-1,018,688
-993,595
-506,169
-256,434
-325,973
-172,919
Tax
Profit After Tax
-1,586,209
-918,508
-1,207,807
-1,018,688
-993,595
-506,169
-256,434
-325,973
-172,919
Dividends Paid
Retained Profit
-1,586,209
-918,508
-1,207,807
-1,018,688
-993,595
-506,169
-256,434
-325,973
-172,919
Employee Costs
1,415,615
1,081,378
762,742
731,674
1,172,618
786,553
506,911
392,781
215,050
Number Of Employees
21
18
14
13
21
14
10
8
5
EBITDA*
-1,586,645
-932,224
-1,193,155
-1,003,373
-979,457
-494,865
-247,282
-317,586
-168,384
* Earnings Before Interest, Tax, Depreciation and Amortisation
Jun 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Mar 2019
Mar 2018
Mar 2017
Mar 2016
Tangible Assets
15,436
43,359
50,171
63,047
69,767
45,286
49,688
52,808
59,170
Intangible Assets
25,024
16,550
19,653
22,062
25,680
17,458
7,816
8,744
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets
40,460
59,909
69,824
85,109
95,447
62,744
57,504
61,552
59,170
Stock & work in progress
200,764
142,723
149,731
91,333
68,016
34,285
33,018
21,825
14,961
Trade Debtors
107,566
119,763
51,270
50,257
66,027
35,528
419
131,219
99
Group Debtors
Misc Debtors
37,887
27,010
262,325
184,414
149,809
113,506
150,366
109,943
108,445
Cash
44,293
645,677
673,293
1,023,660
165,566
46,180
276,550
9,701
120,067
misc current assets
110,117
total current assets
390,510
1,045,290
1,136,619
1,349,664
449,418
229,499
460,353
272,688
243,572
total assets
430,970
1,105,199
1,206,443
1,434,773
544,865
292,243
517,857
334,240
302,742
Bank overdraft
10,725
10,000
10,000
7,500
50,000
Bank loan
Trade Creditors
191,771
91,411
50,365
138,994
120,460
69,130
95,696
62,496
75,327
Group/Directors Accounts
1,169
other short term finances
hp & lease commitments
182
other current liabilities
190,131
33,951
343,957
90,640
134,214
24,945
83,855
141,621
21,334
total current liabilities
392,627
135,362
404,322
237,134
254,856
145,244
179,551
204,117
96,661
loans
10,000
22,500
32,500
42,500
hp & lease commitments
Accruals and Deferred Income
other liabilities
200,000
971,555
provisions
5,390
total long term liabilities
215,390
22,500
32,500
1,014,055
total liabilities
608,017
157,862
436,822
1,251,189
254,856
145,244
179,551
204,117
96,661
net assets
-177,047
947,337
769,621
183,584
290,009
146,999
338,306
130,123
206,081
total shareholders funds
-177,047
947,337
769,621
183,584
290,009
146,999
338,306
130,123
206,081
Jun 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Mar 2019
Mar 2018
Mar 2017
Mar 2016
Operating Activities
Operating Profit
-1,601,327
-942,692
-1,211,049
-1,017,758
-992,176
-505,692
-257,150
-326,135
-173,219
Depreciation
10,165
10,468
15,485
10,767
10,116
9,549
8,940
8,007
4,835
Amortisation
4,517
2,409
3,618
2,603
1,278
928
542
Tax
Stock
58,041
-7,008
58,398
23,317
33,731
1,267
11,193
6,864
14,961
Debtors
-1,320
-166,822
78,924
18,835
66,802
-1,751
-90,377
132,618
108,544
Creditors
100,360
41,046
-88,629
18,534
51,330
-26,566
33,200
-12,831
75,327
Accruals and Deferred Income
156,180
-310,006
253,317
-43,574
109,269
-58,910
-57,766
120,287
21,334
Deferred Taxes & Provisions
5,390
Cash flow from operations
-1,381,436
-1,027,354
-1,165,789
-1,070,565
-919,391
-579,857
-192,664
-349,612
-195,228
Investing Activities
capital expenditure
4,767
-553
-2,609
-4,047
-45,422
-16,067
-5,820
-10,931
-64,005
Change in Investments
cash flow from investments
4,767
-553
-2,609
-4,047
-45,422
-16,067
-5,820
-10,931
-64,005
Financing Activities
Bank loans
Group/Directors Accounts
-1,169
1,169
Other Short Term Loans
Long term loans
-12,500
-10,000
-10,000
42,500
Hire Purchase and Lease Commitments
-182
182
other long term liabilities
200,000
-971,555
971,555
share issue
461,825
1,096,224
1,793,844
912,263
1,136,605
314,862
464,617
250,015
379,000
interest
15,118
24,184
3,242
-930
-1,419
-478
716
162
300
cash flow from financing
664,443
1,110,408
815,531
1,925,206
1,134,199
315,553
465,333
250,177
379,300
cash and cash equivalents
cash
-601,384
-27,616
-350,367
858,094
119,386
-230,370
266,849
-110,366
120,067
overdraft
725
2,500
7,500
-50,000
50,000
change in cash
-602,109
-27,616
-352,867
850,594
169,386
-280,370
266,849
-110,366
120,067
nuvision biotherapies limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for nuvision biotherapies limited. Get real-time insights into nuvision biotherapies limited's credit score, group structure and payment trends.
Perform a competitor analysis for nuvision biotherapies limited by selecting its closest rivals, whether from the MANUFACTURING sector, other small companies, companies in NG90 area or any other competitors across 12 key performance metrics.
nuvision biotherapies limited Ownership
NUVISION BIOTHERAPIES LIMITED group structure
Nuvision Biotherapies Limited has no subsidiary companies.
Ultimate parent company
NUVISION BIOTHERAPIES LIMITED
09526225
NUVISION BIOTHERAPIES LIMITED Shareholders
The largest shareholders in Nuvision Biotherapies Limited include Meif Proof Of Concept & Early Stage Lp and Mercia Meifii.
meif proof of concept & early stage lp
19.35%
mercia meifii
10.68%
the university of nottingham
8.99%
mnl (mercia) nominees limited
8.66%
mnl (mercia) nominees ltd
6.32%
mnl nominees ltd for newable eis scale up fund 3
6.18%
wcs nominees limited as nominee on behalf of the investors in pioneer life science eis knowledge intensive fund
4.81%
roger teasdale
4.45%
kcp nominees (newable) ltd for newable eis scale up fund 3
4.27%
amadeo allentorn farre
2.4%
nuvision biotherapies limited directors
Nuvision Biotherapies Limited currently has 5 directors.
The longest serving directors include
Dr Andrew Hopkinson (May 2015) and
Dr Jonathan Treherne (Jan 2018).
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to nuvision biotherapies limited. Currently there are 1 open charges and 0 have been satisfied in the past.
nuvision biotherapies limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for NUVISION BIOTHERAPIES LIMITED. This can take several minutes, an email will notify you when this has completed.
nuvision biotherapies limitedCompanies House Filings - See Documents
